Casdin Capital, LLC

Insider Reports History

Reporting-owner location: New York, NY
Latest reporting-owner signature: Casdin Partners Master Fund, LP, By: Casdin Partners GP, LLC, its General Partner, By: /s/ Eli Casdin, Managing Member
Source: Latest parsed Forms 3/4/5 signature
Transaction source note: Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Casdin Capital, LLC

Form 4 holding Director, 10%+ Owner

GeneDx Holdings Corp.

Security class: Class A Common Stock, par value $0.0001 per share
Shares / value: 3,707,164
Estimated value: $195,948,084
Report date: 05 Jun 2026
Price: $52.86
Ownership: Indirect

Form 4 holding Director

2seventy bio, Inc.

Security class: Common Stock, par value $0.0001 per share
Shares / value: 2,000,000
Estimated value: $10,199,600
Report date: 10 Jun 2024
Price: $5.10
Ownership: Indirect

Form 4 holding Director

2seventy bio, Inc.

Security class: Total Return Swap
Shares / value: 536,784
Estimated value: $2,531,151
Report date: 10 Jun 2024
Price: $4.72
Ownership: Indirect
Underlying class: Common Stock, par value $0.0001 per share
Underlying amount: 536,784

Form 4 holding Director, 10%+ Owner

GeneDx Holdings Corp.

Security class: Class A Common Stock, par value $0.0001 per share
Shares / value: 20,517
Estimated value: $1,317,601
Report date: 04 Jun 2026
Price: $64.22
Ownership: Direct

Form 4 holding Director

2seventy bio, Inc.

Security class: Common Stock, par value $0.0001 per share
Shares / value: 22,625
Estimated value: $115,383
Report date: 10 Jun 2024
Price: $5.10
Ownership: Direct

Form 4 holding Director

2seventy bio, Inc.

Security class: Stock Options (Right to buy)
Shares / value: 12,050
Estimated value: $47,357
Report date: 10 Jun 2024
Price: $3.93
Ownership: Direct
Underlying class: Common Stock, par value $0.0001 per share
Underlying amount

Form 4 holding Director

2seventy bio, Inc.

Security class: Common Stock, par value $0.0001 per share
Shares / value: 0
Estimated value: $0
Report date: 13 May 2025
Price: $5.00
Ownership: Direct

Form 4 holding Director

2seventy bio, Inc.

Security class: Common Stock, par value $0.0001 per share
Shares / value: 0
Estimated value: $0
Report date: 13 May 2025
Price: $5.00
Ownership: Indirect

Form 4 holding Director, 10%+ Owner

GeneDx Holdings Corp.

Security class: Cash Settled Swap
Shares / value: 850,000
Estimated value
Report date: 11 May 2026
Price
Ownership: Indirect
Underlying class: Class A Common Stock
Underlying amount

Form 4 holding Director

2seventy bio, Inc.

Security class: Stock Options (Right to buy)
Shares / value: 0
Estimated value
Report date: 13 May 2025
Price
Ownership: Direct
Underlying class: Common Stock, par value $0.0001 per share
Underlying amount

Insider Reports Filed by Casdin Capital, LLC

4 WGS

GeneDx Holdings Corp.

Report period: 04 Jun 2026
Transactions: 2
Transaction value: +$11,109,565
Accepted by SEC: 08 Jun 2026, 17:25
Role: Director, 10%+ Owner
Next action: Open filing details

4 WGS

GeneDx Holdings Corp.

Report period: 18 May 2026
Transactions: 3
Transaction value: +$21,459,736
Accepted by SEC: 20 May 2026, 19:45
Role: Director, 10%+ Owner
Next action: Open filing details

4 WGS

GeneDx Holdings Corp.

Report period: 07 May 2026
Transactions: 3
Transaction value: $0
Accepted by SEC: 11 May 2026, 20:43
Role: Director, 10%+ Owner
Next action: Open filing details

4 WGS

GeneDx Holdings Corp.

Report period: 22 Aug 2025
Transactions: 1
Transaction value: -$60,451,950
Accepted by SEC: 22 Aug 2025, 18:55
Role: Director, 10%+ Owner
Next action: Open filing details

4 TSVT

2seventy bio, Inc.

Report period: 13 May 2025
Transactions: 4
Transaction value: -$10,113,125
Accepted by SEC: 15 May 2025, 16:51
Role: Director
Next action: Open filing details

4 WGS

GeneDx Holdings Corp.

Report period: 01 Aug 2024
Transactions: 1
Transaction value: +$13,340,374
Accepted by SEC: 05 Aug 2024, 17:32
Role: Director, 10%+ Owner
Next action: Open filing details

4 TSVT

2seventy bio, Inc.

Report period: 10 Jun 2024
Transactions: 2
Transaction value: +$47,356
Accepted by SEC: 12 Jun 2024, 14:32
Role: Director
Next action: Open filing details

4 WGS

GeneDx Holdings Corp.

Report period: 03 Jun 2024
Transactions: 2
Transaction value: +$2,757,117
Accepted by SEC: 05 Jun 2024, 20:45
Role: Director, 10%+ Owner
Next action: Open filing details

4 WGS

GeneDx Holdings Corp.

Report period: 29 May 2024
Transactions: 1
Transaction value: +$842,604
Accepted by SEC: 31 May 2024, 17:37
Role: Director, 10%+ Owner
Next action: Open filing details

4 WGS

GeneDx Holdings Corp.

Report period: 23 May 2024
Transactions: 3
Transaction value: +$3,424,989
Accepted by SEC: 28 May 2024, 20:40
Role: Director, 10%+ Owner
Next action: Open filing details

4 WGS

GeneDx Holdings Corp.

Report period: 13 May 2024
Transactions: 1
Transaction value: +$1,165,295
Accepted by SEC: 15 May 2024, 18:16
Role: Director, 10%+ Owner
Next action: Open filing details

4 TSVT

2seventy bio, Inc.

Report period: 26 Mar 2024
Transactions: 1
Transaction value: +$203,992
Accepted by SEC: 28 Mar 2024, 20:29
Role: Director
Next action: Open filing details

4 TSVT

2seventy bio, Inc.

Report period: 21 Mar 2024
Transactions: 4
Transaction value: +$3,601,268
Accepted by SEC: 25 Mar 2024, 21:44
Role: Director
Next action: Open filing details

3 TSVT

2seventy bio, Inc.

Report period: 20 Mar 2024
Transactions: 0
Transaction value: $0
Accepted by SEC: 25 Mar 2024, 21:03
Role: Director
Next action: Open filing details

4 WGS

GeneDx Holdings Corp.

Report period: 04 Mar 2024
Transactions: 2
Transaction value: +$357,652
Accepted by SEC: 06 Mar 2024, 19:32
Role: Director, 10%+ Owner
Next action: Open filing details

3 WGS

GeneDx Holdings Corp.

Report period: 31 Jan 2023
Transactions: 0
Transaction value: $0
Accepted by SEC: 10 Feb 2023, 15:05
Role: Director, 10%+ Owner
Next action: Open filing details

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .